Home » Thought Leadership » Blogs

Blogs

1

Showing 3 of 3 posts
Decorative image of blog post depicting biopharma
August 25, 2020 | Blogs

Ten Long-term Impacts of COVID-19 on Biopharma

COVID-19 has presented an abundance of short-term implications and challenges for biopharma companies; however, it is useful to understand and prepare for the longer-term impacts as the acute disruptions to regulatory processes and healthcare delivery begin to subside. To proactively prepare for a post-COVID-19 world, biopharma leaders should develop strategies to integrate technology across the value chain and increase focus on patient centricity in terms of process flows and treatment administration.

covid trial disruptions
April 29, 2020 | Blogs

Clinical Trial Disruptions: Can Small-Cap Biopharma Companies Weather the Impact of COVID-19?

Cumulative costs from patient enrollment scenarios due to COVID-19 will likely generate a significant financial drain on biopharma R&D expenditures. CBPartners' blog post investigates this impact and explores mitigation strategies.

eu in pills
April 14, 2020 | Blogs

The COVID-19 Pandemic: Pricing and Access Outlook for Future Innovative Drugs in Europe

Disruption in healthcare systems across Europe is rife due to the COVID-19 pandemic, with increasingly strained budgets, and shifting healthcare priorities.